Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 274

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

Open access
Görgün, Güllü, Calabrese, Elisabetta, Hideshima, Teru, Ecsedy, Jeffrey, Perrone, Giulia, Mani, Mala, Ikeda, Hiroshi, Bianchi, Giada, Hu, Yiguo, Cirstea, Diana, Santo, Loredana, Tai, Yu-Tzu, Nahar, Sabikun, Zheng, Mei, Bandi, Madhavi, Carrasco, Ruben D., Raje, Noopur, Munshi, Nikhil, Richardson, Paul, Anderson, Kenneth C.·2010·Blood

Abstract

Aurora-A is a mitotic kinase that regulates mitotic spindle formation and segregation. In multiple myeloma (MM), high Aurora-A gene expression has been correlated with centrosome amplification and proliferation; thus, inhibition of Aurora-A in MM may prove to be therapeutically beneficial. Here we assess the in vitro and in vivo anti-MM activity of MLN8237, a small-molecule Aurora-A kinase inhibitor. Treatment of cultured MM cells with MLN8237 results in mitotic spindle abnormalities, mitotic accumulation, as well as inhibition of cell proliferation through apoptosis and senescence. In addition, MLN8237 up-regulates p53 and tumor suppressor genes p21 and p27. Combining MLN8237 with dexamethasone, doxorubicin, or bortezomib induces synergistic/additive anti-MM activity in vitro. In vivo anti-MM activity of MLN8237 was confirmed using a xenograft-murine model of human-MM. Tumor burden was significantly reduced (P = .007) and overall survival was significantly increased (P < .005) in animals treated with 30 mg/kg MLN8237 for 21 days. Induction of apoptosis and cell death by MLN8237 were confirmed in tumor cells excised from treated animals by TdT-mediated dUTP nick end labeling assay. MLN8237 is currently in phase 1 and phase 2 clinical trials in patients with advanced malignancies, and our preclinical results suggest that MLN8237 may be a promising novel targeted therapy in MM.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2009-12-259523

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 274

Metadata

Authors
Görgün, G., Calabrese, E., Hideshima, T., Ecsedy, J., Perrone, G., Mani, M., Ikeda, H., Bianchi, G., Hu, Y., Cirstea, D., Santo, L., Tai, Y.-T., Nahar, S., Zheng, M., Bandi, M., Carrasco, R. D., Raje, N., Munshi, N., Richardson, P., & Anderson, K. C.
Venue
Blood
Published
2010-06-24
Volume
115
Issue
25
Pages
5202-5213
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2126572395
Cited by
274
References
40
FWCI
13.47
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. https://app.cochat.ai/papers/10.1182/blood-2009-12-259523
The paper
Görgün, G., Calabrese, E., Hideshima, T., Ecsedy, J., Perrone, G., Mani, M., Ikeda, H., Bianchi, G., Hu, Y., Cirstea, D., Santo, L., Tai, Y.-T., Nahar, S., Zheng, M., Bandi, M., Carrasco, R. D., Raje, N., Munshi, N., Richardson, P., & Anderson, K. C. (2010). A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. https://doi.org/10.1182/blood-2009-12-259523

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.